Russ Conroy

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.

Treatment with BVd elicited PROs comparable with those who were treated with DVd in relapsed/refractory multiple myeloma.

Belantamab mafodotin plus BPd improved PFS vs PVd in relapsed/refractory multiple myeloma.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.